Myasthenia gravis is a chronic autoimmune, neuromuscular disease that causes weakness in the skeletal muscles (the muscles that connect to your bones and contract to allow body movement in the arms and legs, and allow for breathing).
The global Myasthenia Gravis market is projected to reach US$ 1955.9 million in 2029, increasing from US$ 1185 million in 2022, with the CAGR of 6.4% during the period of 2023 to 2029.
Key companies engaged in the Myasthenia Gravis industry include Takeda, Roche, CSL Limited, Baxter International, Novartis, Bausch Health, Grifols, AstraZeneca and Avadel Pharmaceuticals, etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % value of Myasthenia Gravis were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Myasthenia Gravis market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Myasthenia Gravis market with multiple angles, which provides sufficient supports to readers鈥� strategy and decision making.
By Company
Takeda
Roche
CSL Limited
Baxter International
Novartis
Bausch Health
Grifols
AstraZeneca
Avadel Pharmaceuticals
Octapharma
Astellas Pharma
Zydus Lifesciences
Kedrion S.p.A.
Segment by Type
Monoclonal Antibodies
Intravenous Immunoglobulin
Others
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Myasthenia Gravis report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. 麻豆原创 Opportunities and Challenges
Chapter 3: Companies鈥� Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies鈥� Outline
Chapter 12: 麻豆原创 Conclusions
Chapter 13: Research Methodology and Data Source
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Myasthenia Gravis 麻豆原创 Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Monoclonal Antibodies
1.2.3 Intravenous Immunoglobulin
1.2.4 Others
1.3 麻豆原创 by Application
1.3.1 Global Myasthenia Gravis 麻豆原创 Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Myasthenia Gravis 麻豆原创 Perspective (2018-2029)
2.2 Myasthenia Gravis Growth Trends by Region
2.2.1 Global Myasthenia Gravis 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 Myasthenia Gravis Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 Myasthenia Gravis Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 Myasthenia Gravis 麻豆原创 Dynamics
2.3.1 Myasthenia Gravis Industry Trends
2.3.2 Myasthenia Gravis 麻豆原创 Drivers
2.3.3 Myasthenia Gravis 麻豆原创 Challenges
2.3.4 Myasthenia Gravis 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Myasthenia Gravis Players by Revenue
3.1.1 Global Top Myasthenia Gravis Players by Revenue (2018-2023)
3.1.2 Global Myasthenia Gravis Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global Myasthenia Gravis 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Myasthenia Gravis Revenue
3.4 Global Myasthenia Gravis 麻豆原创 Concentration Ratio
3.4.1 Global Myasthenia Gravis 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Myasthenia Gravis Revenue in 2022
3.5 Myasthenia Gravis Key Players Head office and Area Served
3.6 Key Players Myasthenia Gravis Product Solution and Service
3.7 Date of Enter into Myasthenia Gravis 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Myasthenia Gravis Breakdown Data by Type
4.1 Global Myasthenia Gravis Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global Myasthenia Gravis Forecasted 麻豆原创 Size by Type (2024-2029)
5 Myasthenia Gravis Breakdown Data by Application
5.1 Global Myasthenia Gravis Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global Myasthenia Gravis Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America Myasthenia Gravis 麻豆原创 Size (2018-2029)
6.2 North America Myasthenia Gravis 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Myasthenia Gravis 麻豆原创 Size by Country (2018-2023)
6.4 North America Myasthenia Gravis 麻豆原创 Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Myasthenia Gravis 麻豆原创 Size (2018-2029)
7.2 Europe Myasthenia Gravis 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Myasthenia Gravis 麻豆原创 Size by Country (2018-2023)
7.4 Europe Myasthenia Gravis 麻豆原创 Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Myasthenia Gravis 麻豆原创 Size (2018-2029)
8.2 Asia-Pacific Myasthenia Gravis 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Myasthenia Gravis 麻豆原创 Size by Region (2018-2023)
8.4 Asia-Pacific Myasthenia Gravis 麻豆原创 Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Myasthenia Gravis 麻豆原创 Size (2018-2029)
9.2 Latin America Myasthenia Gravis 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Myasthenia Gravis 麻豆原创 Size by Country (2018-2023)
9.4 Latin America Myasthenia Gravis 麻豆原创 Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Myasthenia Gravis 麻豆原创 Size (2018-2029)
10.2 Middle East & Africa Myasthenia Gravis 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Myasthenia Gravis 麻豆原创 Size by Country (2018-2023)
10.4 Middle East & Africa Myasthenia Gravis 麻豆原创 Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Takeda
11.1.1 Takeda Company Detail
11.1.2 Takeda Business Overview
11.1.3 Takeda Myasthenia Gravis Introduction
11.1.4 Takeda Revenue in Myasthenia Gravis Business (2018-2023)
11.1.5 Takeda Recent Development
11.2 Roche
11.2.1 Roche Company Detail
11.2.2 Roche Business Overview
11.2.3 Roche Myasthenia Gravis Introduction
11.2.4 Roche Revenue in Myasthenia Gravis Business (2018-2023)
11.2.5 Roche Recent Development
11.3 CSL Limited
11.3.1 CSL Limited Company Detail
11.3.2 CSL Limited Business Overview
11.3.3 CSL Limited Myasthenia Gravis Introduction
11.3.4 CSL Limited Revenue in Myasthenia Gravis Business (2018-2023)
11.3.5 CSL Limited Recent Development
11.4 Baxter International
11.4.1 Baxter International Company Detail
11.4.2 Baxter International Business Overview
11.4.3 Baxter International Myasthenia Gravis Introduction
11.4.4 Baxter International Revenue in Myasthenia Gravis Business (2018-2023)
11.4.5 Baxter International Recent Development
11.5 Novartis
11.5.1 Novartis Company Detail
11.5.2 Novartis Business Overview
11.5.3 Novartis Myasthenia Gravis Introduction
11.5.4 Novartis Revenue in Myasthenia Gravis Business (2018-2023)
11.5.5 Novartis Recent Development
11.6 Bausch Health
11.6.1 Bausch Health Company Detail
11.6.2 Bausch Health Business Overview
11.6.3 Bausch Health Myasthenia Gravis Introduction
11.6.4 Bausch Health Revenue in Myasthenia Gravis Business (2018-2023)
11.6.5 Bausch Health Recent Development
11.7 Grifols
11.7.1 Grifols Company Detail
11.7.2 Grifols Business Overview
11.7.3 Grifols Myasthenia Gravis Introduction
11.7.4 Grifols Revenue in Myasthenia Gravis Business (2018-2023)
11.7.5 Grifols Recent Development
11.8 AstraZeneca
11.8.1 AstraZeneca Company Detail
11.8.2 AstraZeneca Business Overview
11.8.3 AstraZeneca Myasthenia Gravis Introduction
11.8.4 AstraZeneca Revenue in Myasthenia Gravis Business (2018-2023)
11.8.5 AstraZeneca Recent Development
11.9 Avadel Pharmaceuticals
11.9.1 Avadel Pharmaceuticals Company Detail
11.9.2 Avadel Pharmaceuticals Business Overview
11.9.3 Avadel Pharmaceuticals Myasthenia Gravis Introduction
11.9.4 Avadel Pharmaceuticals Revenue in Myasthenia Gravis Business (2018-2023)
11.9.5 Avadel Pharmaceuticals Recent Development
11.10 Octapharma
11.10.1 Octapharma Company Detail
11.10.2 Octapharma Business Overview
11.10.3 Octapharma Myasthenia Gravis Introduction
11.10.4 Octapharma Revenue in Myasthenia Gravis Business (2018-2023)
11.10.5 Octapharma Recent Development
11.11 Astellas Pharma
11.11.1 Astellas Pharma Company Detail
11.11.2 Astellas Pharma Business Overview
11.11.3 Astellas Pharma Myasthenia Gravis Introduction
11.11.4 Astellas Pharma Revenue in Myasthenia Gravis Business (2018-2023)
11.11.5 Astellas Pharma Recent Development
11.12 Zydus Lifesciences
11.12.1 Zydus Lifesciences Company Detail
11.12.2 Zydus Lifesciences Business Overview
11.12.3 Zydus Lifesciences Myasthenia Gravis Introduction
11.12.4 Zydus Lifesciences Revenue in Myasthenia Gravis Business (2018-2023)
11.12.5 Zydus Lifesciences Recent Development
11.13 Kedrion S.p.A.
11.13.1 Kedrion S.p.A. Company Detail
11.13.2 Kedrion S.p.A. Business Overview
11.13.3 Kedrion S.p.A. Myasthenia Gravis Introduction
11.13.4 Kedrion S.p.A. Revenue in Myasthenia Gravis Business (2018-2023)
11.13.5 Kedrion S.p.A. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Takeda
Roche
CSL Limited
Baxter International
Novartis
Bausch Health
Grifols
AstraZeneca
Avadel Pharmaceuticals
Octapharma
Astellas Pharma
Zydus Lifesciences
Kedrion S.p.A.
听
听
*If Applicable.
